About Kerecis
Kerecis is a company based in Isafjordur (Iceland) founded in 2007 was acquired by Coloplast in July 2023. Kerecis has raised $93.11 million across 14 funding rounds from investors including SVB, Coloplast and European Union. The company has 150 employees as of December 31, 2021. Kerecis has completed 1 acquisition, including Phytoceuticals. Kerecis offers products and services including MariGen, SurgiClose, SurgiBind, GraftGuide, and Shield. Kerecis operates in a competitive market with competitors including BONESUPPORT, Sofregen, Lamellar, Arsenal Medical and Cerapedics, among others.
- Headquarter Isafjordur, Iceland
- Employees 150 as on 31 Dec, 2021
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kerecis, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$93.11 M (USD)
in 14 rounds
-
Latest Funding Round
$30 M (USD), Series D
Jul 26, 2022
-
Investors
SVB
& 7 more
-
Employee Count
150
as on Dec 31, 2021
- Investments & Acquisitions
-
Acquired by
Coloplast
(Jul 06, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kerecis
Kerecis offers a comprehensive portfolio of products and services, including MariGen, SurgiClose, SurgiBind, GraftGuide, and Shield.
Fish skin graft for treating chronic wounds and ulcers.
Combination graft for soft-tissue repair in trauma.
Product for burn wound healing and regeneration.
Guide for applying fish skin in surgical procedures.
Fish skin product for private office wound care.
Solutions for animal wound treatment and healing.
People of Kerecis
Unlock access to complete
Sales and Marketing
38 people
Leadership Team
28 people
Regenerative Team
23 people
Software Development Team
11 people
Product Management Team
11 people
Finance and Accounting
6 people
Human Resources and Administration
2 people
Senior Team
2 people
Unlock access to complete
Funding Insights of Kerecis
Kerecis has successfully raised a total of $93.11M across 14 strategic funding rounds. The most recent funding activity was a Series D round of $30 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kerecis
Kerecis has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, Coloplast and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
KIRKBI is engaged in building a better future for children.
|
Locked | Locked | Locked | |
|
A venture capital fund focused on supporting innovative startups in Iceland.
|
Locked | Locked | Locked | |
|
Banking services are provided to innovative companies, investors, and individuals.
|
Locked | Locked | Locked |
Investor details for Kerecis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kerecis
Kerecis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Phytoceuticals.
Investment portfolio details for Kerecis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Wound healing products are manufactured by Phytoceuticals in Switzerland.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Kerecis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Kerecis
Detailed financials for Kerecis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kerecis Comparisons
Peer comparison for Kerecis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kerecis
Kerecis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BONESUPPORT, Sofregen, Lamellar, Arsenal Medical and Cerapedics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Injectable synthetic bone substitutes are developed for fracture treatment.
|
|
| Locked | Locked | Locked |
Silk-derived biomaterials are developed for soft tissue repair in surgery.
|
|
| Locked | Locked | Locked |
Develops patented medical devices and pharmaceuticals based on mimetics of extra-alveolar lamellar bodies
|
|
| Locked | Locked | Locked |
Polymer-based foams and fibers are developed for medical applications.
|
|
| Locked | Locked | Locked |
Osteobiologic products are developed using synthetic peptide technology.
|
Detailed competitors of Kerecis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kerecis
Complete news archive for Kerecis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kerecis
Kerecis was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Kerecis is headquartered in Isafjordur, Iceland.
Kerecis is a funded company, having raised a total of $93.11M across 14 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Kerecis is 150.
Founded in 2007 in Isafjordur, Iceland, the company operates in the medical technology sector, focusing on acellular fish-skin grafts. Omega3 technology is utilized in products for chronic wound management, hernia repair, breast reconstruction, and abdominal wall reconstruction. Advantages over human and porcine alternatives include better economics, enhanced clinical outcomes, lower disease transmission risks, and no cultural usage barriers. The domain kerecis.com supports global operations.
Kerecis's top competitors include BONESUPPORT, Kitotech Medical and Cerapedics.
Kerecis offers MariGen, SurgiClose, SurgiBind, GraftGuide, and 2 more products and services.
Kerecis has made 1 acquisition, including Phytoceuticals.
Kerecis has 8 investors. Key investors include SVB, Coloplast, European Union, KIRKBI, and LSR.
The valuation of Kerecis is $620M as of Jul 2022.